Loading...
XTAEPPBT
Market cap1.77bUSD
Dec 20, Last price  
6.30ILS
1D
-8.70%
1Q
-53.33%
Jan 2017
-99.47%
Name

Purple Biotech Ltd

Chart & Performance

D1W1MN
XTAE:PPBT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
62.48%
Rev. gr., 5y
115.44%
Revenues
0k
P
00000901,0001,000,0001,000,0001,000,000-320,000-910,0000
Net income
-20m
L-4.54%
-703-2,628,000-5,252,000-4,202,000-12,125,000-12,272,000-5,200,000-6,109,000-12,405,000-18,463,000-20,825,000-19,880,000
CFO
-19m
L+14.88%
-253-512,000-4,526,000-3,308,000-6,262,000-8,627,000-8,480,000-5,581,000-12,092,000-15,071,000-16,735,000-19,226,000
Dividend
Oct 30, 201295.9805 ILS/sh
Earnings
Mar 03, 2025

Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
URL
https://purple-biotech.com/
IPO date
Sep 03, 1978
Employees
20
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
(910)
184.38%
(320)
-132.00%
Cost of revenue
17,230
22,804
18,165
Unusual Expense (Income)
NOPBT
(17,230)
(23,714)
(18,485)
NOPBT Margin
2,605.93%
5,776.56%
Operating Taxes
(935)
637
Tax Rate
NOPAT
(17,230)
(22,779)
(19,122)
Net income
(19,880)
-4.54%
(20,825)
12.79%
(18,463)
48.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,563
1,498
564
BB yield
-0.05%
-0.29%
-0.04%
Debt
Debt current
188
194
199
Long-term debt
514
836
1,299
Deferred revenue
Other long-term liabilities
2,659
145
292
Net debt
(14,710)
(31,083)
(45,889)
Cash flow
Cash from operating activities
(19,226)
(16,735)
(15,071)
CAPEX
(228)
(115)
Cash from investing activities
13,881
19,914
13,406
Cash from financing activities
5,449
1,114
1,512
FCF
(17,018)
(22,565)
(19,050)
Balance
Cash
15,412
32,113
47,200
Long term investments
187
Excess cash
15,412
32,158
47,403
Stockholders' equity
(98,887)
(107,328)
(86,862)
Invested Capital
136,194
155,086
153,009
ROIC
ROCE
EV
Common stock shares outstanding
221,332
18,482
17,800
Price
15.60
-43.48%
27.60
-64.52%
77.80
2.10%
Market cap
3,452,779
576.90%
510,090
-63.17%
1,384,848
5.60%
EV
3,438,159
479,194
1,339,238
EBITDA
(17,033)
(23,513)
(18,254)
EV/EBITDA
Interest
2,182
126
212
Interest/NOPBT